Market Research Industry Reports

Aeglea BioTherapeutics Inc (AGLE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Summary

Aeglea BioTherapeutics Inc (Aeglea BioTherapeutics), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the treatment of cancer and rare genetic diseases. The companys product pipeline comprises AEB1102, AEB3103, AEB2109, and AEB4104. It develops engineered human enzymes to target and degrade amino acids in the blood. Aeglea BioTherapeutics is developing products for the treatment of Arginase I Deficiency; homocystinuria and others. The company works in partnership with research institutions, allied healthcare providers and pharmaceutical companies to discover, develop and market new product candidates. Aeglea BioTherapeutics is headquartered in Austin, Texas, the US.

Aeglea BioTherapeutics Inc (AGLE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

2
List of Tables 4
List of Figures 5
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 11
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 12
Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 13
Licensing Agreements 13
AEMase Enters into Licensing Agreement with University of Texas at Austin 13
AECase Enters into Licensing Agreement with University of Texas at Austin 14
Equity Offering 15
Aeglea BioTherapeutics Prices Public Offering of Shares for USD12.3 Million 15
Aeglea BioTherapeutics Raises USD54.8 million in IPO 16
Aeglea BioTherapeutics Inc - Key Competitors 18
Key Employees 19
Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
May 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results 21
Mar 23, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results 22
Nov 09, 2016: Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2016 Financial Results 24
Aug 09, 2016: Aeglea BioTherapeutics Announces Second Quarter 2016 Financial Results 26
May 19, 2016: Aeglea BioTherapeutics Announces First Quarter 2016 Financial Results 28
Corporate Communications 29
Jul 10, 2017: Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer 29
Feb 16, 2017: Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors 30
May 16, 2016: Aeglea BioTherapeutics Names Dr. Sandra Rojas-Caro as Chief Medical Officer 31
Mar 15, 2016: Aeglea BioTherapeutics Appoints Dr. Anthony Quinn to Board of Directors 32
Product News 33
Nov 08, 2016: Aeglea BioTherapeutics to Present a Poster at the Society for Immunotherapy of Cancer 2016 Annual Meeting Suggesting Potential for AEB1102 Combination Therapy with Immuno-Oncology Checkpoint Inhibitors 33
Product Approvals 34
May 23, 2016: Aeglea BioTherapeutics Receives FDA Fast Track Designation for AEB1102 for the Treatment of Patients with Hyperargininemia Secondary to Arginase I Deficiency 34
Mar 14, 2016: Aeglea BioTherapeutics Announces FDA Acceptance of its Investigational New Drug Application for AEB1102 for the Treatment of Hematological Malignancies 35
Jan 07, 2016: Aeglea BioTherapeutics Announces FDA Acceptance of Its Investigational New Drug Application for AEB1102 for the Treatment of Arginase I Deficiency 36
Clinical Trials 37
Sep 15, 2016: Aeglea BioTherapeutics Doses First Patients in Phase 1 Trial of AEB1102 for the Treatment of Arginase I Deficiency 37
Aug 29, 2016: Aeglea BioTherapeutics Doses First Patient in Phase 1 Trial of AEB1102 for the Treatment of Hematological Malignancies 38
Jul 18, 2016: Aeglea BioTherapeutics Provides Update on AEB1102 Clinical Program in Rare Diseases and Cancer 39
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List Of Tables


Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aeglea BioTherapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 11
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 12
Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 13
AEMase Enters into Licensing Agreement with University of Texas at Austin 13
AECase Enters into Licensing Agreement with University of Texas at Austin 14
Aeglea BioTherapeutics Prices Public Offering of Shares for USD12.3 Million 15
Aeglea BioTherapeutics Raises USD54.8 million in IPO 16
Aeglea BioTherapeutics Inc, Key Competitors 18
Aeglea BioTherapeutics Inc, Key Employees 19
Aeglea BioTherapeutics Inc, Subsidiaries 20

List Of Figures


Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Aeglea BioTherapeutics Inc (AGLE) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Aeglea BioTherapeutics Inc (Aeglea BioTherapeutics), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the treatment of cancer and rare genetic diseases.

USD 250View Report

Aeglea BioTherapeutics Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Aeglea BioTherapeutics Inc Company Profile is a detailed strategic and analytical report on Aeglea BioTherapeutics Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200View Report

Aeglea BioTherapeutics Inc (AGLE) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Aeglea BioTherapeutics Inc (Aeglea BioTherapeutics), formerly Aeglea BioTherapeutics Holdings, LLC is a biotechnology company that develops and commercializes engineered human enzymes for the treatment of cancer and rare genetic diseases.

USD 250View Report

Iovance Biotherapeutics Inc (IOVA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Iovance Biotherapeutics Inc (Iovance), formerly Lion Biotechnologies Inc is a biotechnology company that focuses on developing novel cancer immunotherapy products for treating various cancers. It develops products based on tumor-infiltrating

USD 250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 250
  • Site Licence    USD 500
  • Enterprise Wide Licence    USD 750
$ 250

Reports Details

Published Date : Jul 2017
No. of Pages :41
Country :United States of America
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube